Worldwide Network for Blood and Marrow Transplantation (WBMT) Recommendations Regarding Essential Medications Required To Establish An Early Stage Hematopoietic Cell Transplantation Program.

Journal Article (Journal Article)

Establishing a hematopoietic cell transplantation (HCT) program is complex. Planning is essential while establishing such a program to overcome the expected challenges. Authorities involved in HCT program establishment will need to coordinate the efforts between the different departments required to start up the program. One essential department is pharmacy and the medications required. To help facilitate this, the Worldwide Network for Blood and Marrow Transplantation organized a structured survey to address the essential medications required to start up an HCT program. A group of senior physicians and pharmacists prepared a list of the medications used at the different phases of transplantation. These drugs were then rated by a questionnaire using a scale of necessity based on the stage of development of the transplant program. The questionnaire was sent to 30 physicians, in different parts of the world, who have between 5 and 40 years of experience in autologous and/or allogeneic transplantation. This group of experts scored each medication on a 7-point scale, ranging from an absolute requirement (score of 1) to not required (score of 7). The results are presented here to help guide the prioritization of required medications.

Full Text

Duke Authors

Cited Authors

  • El Fakih, R; Greinix, H; Koh, M; Shaw, B; Mohty, M; Al Nahedh, M; Saber, W; Kharfan-Dabaja, MA; Perales, M-A; Savani, BN; Majhail, NS; Passweg, JR; Sureda, A; Ahmed, SO; Gluckman, E; Riches, M; El-Jawahri, A; Rondelli, D; Srivastava, A; Faulkner, L; Atsuta, Y; Ballen, KK; Rasheed, W; Okamoto, S; Seber, A; Chao, N; Kröger, N; Kodera, Y; Szer, J; Hashmi, SK; Horowitz, MM; Weisdorf, D; Niederwieser, D; Aljurf, M

Published Date

  • March 2021

Published In

Volume / Issue

  • 27 / 3

Start / End Page

  • 267.e1 - 267.e5

PubMed ID

  • 33781535

Electronic International Standard Serial Number (EISSN)

  • 2666-6367

Digital Object Identifier (DOI)

  • 10.1016/j.jtct.2020.12.015


  • eng

Conference Location

  • United States